rhBNP治疗AHF的临床疗效及对血流动力学及炎症因子的影响

发布时间：2018-10-08 07:35

【摘要】：目的通过观察急性心力衰竭(AHF)患者治疗前后血流动力学参数、心功能及炎症因子水平变化,探讨重组人脑利钠肽(rhBNP)治疗AHF的临床疗效及安全性。方法将2012年6月至2015年12月聊城市中医医院收治的96例AHF患者分为对照组及观察组各48例,两组均给予常规抗心衰治疗,观察组静脉滴注rhBNP,对照组静脉滴注硝普钠,每组选取15例监测血流动力学变化,观察临床疗效,测定用药前后心率、血压、尿量、心功能指标及血浆N末端脑钠肽前体(NT-proBNP)、白细胞介素-6(IL-6)、超敏C反应蛋白(hs-CRP)水平变化,观察不良反应发生情况。结果观察组总有效率明显高于对照组(P0.05),观察组用药后各时间点肺动脉压(PAP)、肺毛细血管压(PCWP)明显低于用药前,两组PAP、PCWP比较差异有统计学意义(P0.05);用药后两组心率、收缩压、NT-proBNP、IL-6、hs-CRP水平均明显降低,尿量、左室射血分数(LVEF)明显增加,两组比较差异有统计学意义(P0.05);两组不良反应发生率比较差异无统计学意义(P0.05)。结论 rhBNP治疗急性心力衰竭短期疗效优于硝普钠,可改善患者血流动力学及心功能,降低炎症因子水平。
[Abstract]:Objective to investigate the clinical efficacy and safety of recombinant human brain natriuretic peptide (rhBNP) in the treatment of acute heart failure (AHF) by observing the changes of hemodynamic parameters, cardiac function and inflammatory factors before and after treatment. Methods from June 2012 to December 2015, 96 patients with AHF were divided into two groups: control group (n = 48) and observation group (n = 48). Both groups were treated with routine anti-heart failure therapy. The observation group was treated with rhBNP, and the control group was treated with sodium nitroprusside. 15 patients in each group were selected to observe the hemodynamic changes, clinical efficacy, heart rate, blood pressure, urine volume, cardiac function and plasma levels of N-terminal brain natriuretic peptide precursor (NT-proBNP), interleukin-6 (IL-6), hypersensitive C-reactive protein (hs-CRP) before and after treatment. Adverse reactions were observed. Results the total effective rate of the observation group was significantly higher than that of the control group (P0.05). The pulmonary artery pressure (PAP),) pulmonary capillary pressure (PCWP) in the observation group was significantly lower than that before the treatment (P0.05), the heart rate of the two groups was significantly lower than that of the control group (P0.05). NT-proBNPP IL-6hs-CRP levels were significantly decreased, urine volume and left ventricular ejection fraction (LVEF) were significantly increased in both groups (P0.05), and there was no significant difference in the incidence of adverse reactions between the two groups (P0.05). Conclusion rhBNP is superior to sodium nitroprusside in the treatment of acute heart failure. It can improve hemodynamics and cardiac function and decrease the level of inflammatory factors.
【作者单位】：山东省聊城市中医医院重症医学科;山东大学齐鲁医院心血管内科;
【基金】：国家自然科学基金资助项目(81070141)
【分类号】：R541.6

【相似文献】